Recommendations for the disease-modifying treatments of early Alzheimer's disease.
10.3760/cma.j.cn112138-20241028-00709
- Collective Name:Expert Consensus Review Committee on Disease-Modifying Treatments for Early Alzheimer′s Disease
- Publication Type:Journal Article
- MeSH:
Humans;
Alzheimer Disease/drug therapy*;
Amyloid beta-Peptides
- From:
Chinese Journal of Internal Medicine
2025;64(5):385-395
- CountryChina
- Language:Chinese
-
Abstract:
Monoclonal antibodies targeting β-amyloid (Aβ)(represented by Lecanemab) have been approved in the United States, Japan and China for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia, and AD treatment has moved towards the era of disease modifying therapy (DMT). In view of the lack of use experience with DMT in China, this article presents recommendations for Aβ-based DMT clinical practice based on its clinical evidence, as well as its existing usage experience and research regarding AD. These recommendations include the mechanism of action, patient selection, standardized use, effectiveness, and safety monitoring, intending to help guide the rational use in real-world clinical practice.
